Publication Date
4-1-2023
Journal
Heart Failure - JACC
DOI
10.1016/j.jchf.2022.12.005
PMID
36881398
PMCID
PMC10248756
PubMedCentral® Posted Date
6-8-2023
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Aged, Heart Failure, Biomarkers, Prognosis, Atherosclerosis, Echocardiography, Natriuretic Peptide, Brain, Peptide Fragments, heart failure stages, pre-heart failure, cardiovascular risk, heart failure prevention, Stage B heart failure
Abstract
BACKGROUND: The recent heart failure (HF) guideline recommends the inclusion of cardiac biomarkers in defining Stage B HF.
OBJECTIVES: The authors evaluated the impact of incorporating cardiac biomarkers to reclassify HF in 5,324 participants (mean age: 75.8 years) without prevalent HF enrolled in the ARIC (Atherosclerosis Risk In Communities) study and assessed prognosis of Stage B using cardiac biomarkers.
METHODS: Using N-terminal pro-B-type natriuretic peptide (/mL or ≥125 pg/mL), high-sensitivity troponin T (/L or ≥14 ng/L), and abnormal cardiac structure/function by echocardiography, individuals were classified as Stage A
RESULTS: Overall, 4,326 (81.3%) individuals were classified as Stage B
CONCLUSIONS: Incorporating biomarkers based on the new HF guideline reclassified approximately 1 in 5 older adults without prevalent HF to Stage B. The routine measurement of biomarkers can help to identify individuals at higher HF risk who may benefit most from HF prevention efforts.
Comments
Associated Data